Sherry X Yang

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 28:2974-81. 2010
  2. ncbi request reprint Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer
    Sherry X Yang
    Cancer Therapeutics Branch in Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 11:6226-32. 2005
  3. pmc Bevacizumab and breast cancer: current therapeutic progress and future perspectives
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Building, 37 Room 1048, 37 Convent Drive, Bethesda, MD 20892 USA
    Expert Rev Anticancer Ther 9:1715-25. 2009
  4. pmc Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5893-9. 2008
  5. doi request reprint p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bldg 37 Rm 1048, Bethesda, MD 20892, USA
    Int J Oncol 38:1445-52. 2011
  6. ncbi request reprint Circulating biomarkers of bevacizumab activity in patients with breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
    Cancer Biol Ther 7:15-20. 2008
  7. ncbi request reprint Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
    J Clin Oncol 25:3421-7. 2007
  8. ncbi request reprint Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas
    Sherry X Yang
    Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Biol Ther 8:2004-9. 2009
  9. doi request reprint Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer
    Chia C Portera
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 14:2710-6. 2008
  10. ncbi request reprint Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncol Rep 17:281-7. 2007

Collaborators

Detail Information

Publications19

  1. pmc Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 28:2974-81. 2010
    ....
  2. ncbi request reprint Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer
    Sherry X Yang
    Cancer Therapeutics Branch in Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
    Clin Cancer Res 11:6226-32. 2005
    ....
  3. pmc Bevacizumab and breast cancer: current therapeutic progress and future perspectives
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Building, 37 Room 1048, 37 Convent Drive, Bethesda, MD 20892 USA
    Expert Rev Anticancer Ther 9:1715-25. 2009
    ..The biomarkers of benefit will ultimately help identify the subgroups of patients who specifically benefit from anti-VEGF therapy with bevacizumab...
  4. pmc Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5893-9. 2008
    ..To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD)...
  5. doi request reprint p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bldg 37 Rm 1048, Bethesda, MD 20892, USA
    Int J Oncol 38:1445-52. 2011
    ..Our data suggest that baseline p53, apoptosis and HER2 are each significantly associated with outcome in patients who received bevacizumab plus chemotherapy...
  6. ncbi request reprint Circulating biomarkers of bevacizumab activity in patients with breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
    Cancer Biol Ther 7:15-20. 2008
    ..Tumor samples were evaluated for VEGFR-2 mutations before and after bevacizumab...
  7. ncbi request reprint Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
    J Clin Oncol 25:3421-7. 2007
    ..Ixabepilone was evaluated for efficacy and safety in a phase II clinical trial for women with metastatic breast cancer...
  8. ncbi request reprint Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas
    Sherry X Yang
    Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Biol Ther 8:2004-9. 2009
    ..We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute...
  9. doi request reprint Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer
    Chia C Portera
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 14:2710-6. 2008
    ..To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy...
  10. ncbi request reprint Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray
    Sherry X Yang
    National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Oncol Rep 17:281-7. 2007
    ..20 and 0.31; all P>0.15). The significant association of eIF4E with VEGF and cyclin D1 in multiple tumors supports a role for eIF4E in translational regulation of proteins related to angiogenesis and growth...
  11. ncbi request reprint Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
    Suparna Bonthala Wedam
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 8901 Wisconsin Avenue, Building 8, Rm 5101, Bethesda, MD 20889 5015, USA
    J Clin Oncol 24:769-77. 2006
    ..Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, was administered to previously untreated patients to evaluate parameters of angiogenesis...
  12. ncbi request reprint PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors
    Kenneth Steadman
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cell Cycle 7:818-29. 2008
    ..We conclude that while spheroids (and confluent monolayer cells) show drug resistance, the mechanisms underlying this resistance diverge from those conferring resistance to intractable cancers...
  13. pmc Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent
    Diana Nguyen
    Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 10:4074-82. 2011
    ..Abrogating the cell-cycle arrest induced by PARP inhibition plus chemotherapeutics may be a strategy in the treatment of BRCA-proficient cancer...
  14. pmc Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody
    Yonghzong Wu
    Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Oncol 42:1229-38. 2013
    ....
  15. ncbi request reprint A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer
    Neelima Denduluri
    Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Clin Breast Cancer 6:460-3. 2005
  16. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
    Jennifer A Low
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889 5015, USA
    J Clin Oncol 23:2726-34. 2005
    ..In a phase II trial, we evaluated the efficacy and safety of ixabepilone in women with metastatic and locally advanced breast cancer...
  17. ncbi request reprint Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
    William L Dahut
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 5:22-7. 2006
    ..To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors...
  18. doi request reprint Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
    Naoko Takebe
    Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, United States Electronic address
    Pharmacol Ther 141:140-9. 2014
    ..Biomarkers of efficacy or benefit may be of importance for a successful development of this class of drugs. ..
  19. pmc Designing phase 0 cancer clinical trials
    Anthony J Murgo
    Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 2440, USA
    Clin Cancer Res 14:3675-82. 2008
    ....